The Increased Type-1 and Type-2 Chemokine Levels in Children with Acute RSV Infection Alter the Development of Adaptive Immune Responses
Table 2
Demographic description of tested groups and clinical data of RSV-infected children. For basic statistic data analysis median was used with minimum and maximum range written in parenthesis; marks number; N/A marks nonavailable data.
RSV
Non-RSV
Controls
17
11
18
Convalescence ()
7
6
N/A
Age (months)
3.5 (0.5–14)
16 (2–22.4)
10.5 (0.1–22.4)
Gender (% of male)
58.82
36.36
66.66
Family history of atopy (% of subjects)
23.53
9.09
0
Days of symptoms at the time of sample collection
5 (2–10)
4 (2–10)
N/A
Length of hospitalization (day)
5 (1–14)
5 (1–13)
N/A
Wheezing presence (% of subjects)
70.59
0
0
Wheezing duration* (days)
3 (1–10)
N/A
N/A
O2 saturation (%)
92 (78–94.6)
>95
N/A
Length of O2 supplementation** (days)
5 (2–7)
N/A
N/A
Heart rate (beats/minute)
145 (134–176)
138+ (130–160)
N/A
Respiratory frequency (breath/minute)
48 (36–80)
33.5+ (24–60)
N/A
White blood cell count (×109/L)
9.6 (5.5–17.1)
19.6 (5.0–36.1)
N/A
CRP (mg/L)
4 (0–44.7)
58.3 (3.4–137)
N/A
Disease severity score
7 (5–19)
5 (3–9)
N/A
Only for patients with confirmed wheezing.
**Only for patients that needed O2 supplementation.
+Exact values familiar only for 4 patients, the rest were marked as normal values.
